Related Experiment Video
Updated: Jul 6, 2026
10:35
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
[Antiandrogen gynecomastia: an inescapable harm? Radiotherapy: a simple and efficient solution!]
Philippe A Couke1, Patrice Jichliski, Oscar Matzinger
1Service de Radio-Oncologie, Centre Hospitalier Universitaire Vaudois Lausanne.
Revue Medicale De La Suisse Romande
|April 21, 2004
Summary
Anti-androgen treatment for prostate cancer can cause gynecomastia, a painful side effect. Radiotherapy is recommended for early-stage or prophylactic treatment, offering a safe and effective solution to improve patient quality of life.
Area of Science:
- Oncology
- Endocrinology
Context:
- Hormonal therapy for prostate cancer often involves anti-androgens.
- This treatment can lead to gynecomastia due to estrogen-androgen imbalance.
- Gynecomastia negatively impacts patient quality of life, often accompanied by mastodynia.
Purpose:
- To review the management of anti-androgen-induced gynecomastia in prostate cancer patients.
- To highlight radiotherapy as a primary treatment option for early-stage and prophylactic management.
- To discuss the limitations of current medical treatments for this condition.
Summary:
- Anti-androgen therapy for prostate cancer frequently causes gynecomastia, impacting quality of life.
- Radiotherapy is the preferred treatment for early-stage gynecomastia and can be used prophylactically.
- Established gynecomastia with fibrosis may require surgical intervention.
Impact:
- Radiotherapy offers a safe, well-tolerated, and effective treatment for gynecomastia.
- Successful management of gynecomastia can significantly improve the quality of life for prostate cancer patients.
- Further research into effective and safe medical treatments is warranted.
